Compare PFBC & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PFBC | ERAS |
|---|---|---|
| Founded | 1991 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 1998 | 2021 |
| Metric | PFBC | ERAS |
|---|---|---|
| Price | $87.34 | $10.58 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $102.67 | $5.78 |
| AVG Volume (30 Days) | 106.8K | ★ 9.8M |
| Earning Date | 01-22-2026 | 03-19-2026 |
| Dividend Yield | ★ 3.73% | N/A |
| EPS Growth | ★ 7.99 | N/A |
| EPS | ★ 10.41 | N/A |
| Revenue | ★ $281,236,000.00 | N/A |
| Revenue This Year | $5.05 | N/A |
| Revenue Next Year | $9.42 | N/A |
| P/E Ratio | $8.24 | ★ N/A |
| Revenue Growth | ★ 5.27 | N/A |
| 52 Week Low | $71.90 | $1.01 |
| 52 Week High | $103.05 | $10.71 |
| Indicator | PFBC | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 40.73 | 79.74 |
| Support Level | $82.64 | $9.05 |
| Resistance Level | $85.35 | $10.71 |
| Average True Range (ATR) | 3.60 | 0.91 |
| MACD | -0.89 | 0.04 |
| Stochastic Oscillator | 32.19 | 92.24 |
Preferred Bank is a commercial bank located in California. Its products and services are divided into Personal Banking, Business Banking, and Commercial Banking which includes Checking accounts, Savings accounts, CDs, Loans and Credit, Electronic banking, and Treasury Management. It provides personalized deposit services, real estate finance, commercial loans, and trade finance credit facilities to small and mid-sized businesses and their owners, entrepreneurs, real estate developers and investors, professionals, and high-net-worth individuals. The bank generates a majority of its revenue from Southern and Northern California and Flushing.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.